JP2022517618A5 - - Google Patents
Info
- Publication number
- JP2022517618A5 JP2022517618A5 JP2021541017A JP2021541017A JP2022517618A5 JP 2022517618 A5 JP2022517618 A5 JP 2022517618A5 JP 2021541017 A JP2021541017 A JP 2021541017A JP 2021541017 A JP2021541017 A JP 2021541017A JP 2022517618 A5 JP2022517618 A5 JP 2022517618A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- hematopoietic stem
- genetically modified
- progenitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025202676A JP2026035683A (ja) | 2019-01-16 | 2025-11-25 | 系統特異的抗原の阻害のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962793210P | 2019-01-16 | 2019-01-16 | |
| US62/793,210 | 2019-01-16 | ||
| US201962852573P | 2019-05-24 | 2019-05-24 | |
| US62/852,573 | 2019-05-24 | ||
| PCT/US2020/013887 WO2020150478A1 (en) | 2019-01-16 | 2020-01-16 | Compositions and methods for inhibition of lineage specific antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025202676A Division JP2026035683A (ja) | 2019-01-16 | 2025-11-25 | 系統特異的抗原の阻害のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517618A JP2022517618A (ja) | 2022-03-09 |
| JP2022517618A5 true JP2022517618A5 (https=) | 2023-01-25 |
| JP7784707B2 JP7784707B2 (ja) | 2025-12-12 |
Family
ID=71613437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541017A Active JP7784707B2 (ja) | 2019-01-16 | 2020-01-16 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2025202676A Pending JP2026035683A (ja) | 2019-01-16 | 2025-11-25 | 系統特異的抗原の阻害のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025202676A Pending JP2026035683A (ja) | 2019-01-16 | 2025-11-25 | 系統特異的抗原の阻害のための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210260130A1 (https=) |
| EP (1) | EP3911338A4 (https=) |
| JP (2) | JP7784707B2 (https=) |
| KR (1) | KR20210129048A (https=) |
| CN (1) | CN113474452A (https=) |
| AU (1) | AU2020209218A1 (https=) |
| BR (1) | BR112021014010A2 (https=) |
| CA (1) | CA3126677A1 (https=) |
| IL (1) | IL284853A (https=) |
| MX (1) | MX2021008490A (https=) |
| SG (1) | SG11202107639UA (https=) |
| WO (1) | WO2020150478A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| AU2020280103A1 (en) * | 2019-05-23 | 2021-12-23 | Vor Biopharma Inc. | Compositions and methods for CD33 modification |
| AU2020338011A1 (en) * | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CLL1 modification |
| WO2022047168A1 (en) * | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| WO2022093983A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for treating hematopoietic malignancy |
| CN120249215A (zh) * | 2021-04-27 | 2025-07-04 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| AU2022324093A1 (en) | 2021-08-02 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| BG113932A (bg) * | 2024-07-19 | 2026-01-30 | Медицински университет – Пловдив | Панели и китове от реагенти за измерване на минимална резидуална болест при детска в-клетъчна прекурсорна остра лимфобластна левкемия чрез имунофенотипизация |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795221B (zh) * | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| CN108064176A (zh) * | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| CA2986310A1 (en) * | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| AU2016337525B2 (en) * | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| KR20180118111A (ko) * | 2015-12-23 | 2018-10-30 | 크리스퍼 테라퓨틱스 아게 | 근위축성 측색 경화증 및/또는 전두측두엽 퇴행의 치료 물질 및 방법 |
| EP3585895A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Compositions and methods for gene editing |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
-
2020
- 2020-01-16 BR BR112021014010-7A patent/BR112021014010A2/pt unknown
- 2020-01-16 SG SG11202107639UA patent/SG11202107639UA/en unknown
- 2020-01-16 EP EP20740954.1A patent/EP3911338A4/en active Pending
- 2020-01-16 CA CA3126677A patent/CA3126677A1/en active Pending
- 2020-01-16 AU AU2020209218A patent/AU2020209218A1/en active Pending
- 2020-01-16 JP JP2021541017A patent/JP7784707B2/ja active Active
- 2020-01-16 KR KR1020217025362A patent/KR20210129048A/ko active Pending
- 2020-01-16 MX MX2021008490A patent/MX2021008490A/es unknown
- 2020-01-16 WO PCT/US2020/013887 patent/WO2020150478A1/en not_active Ceased
- 2020-01-16 CN CN202080014774.3A patent/CN113474452A/zh active Pending
-
2021
- 2021-04-29 US US17/244,136 patent/US20210260130A1/en active Pending
- 2021-07-14 IL IL284853A patent/IL284853A/en unknown
-
2025
- 2025-11-25 JP JP2025202676A patent/JP2026035683A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517618A5 (https=) | ||
| JP7168641B2 (ja) | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 | |
| Li et al. | Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity | |
| JP7411578B2 (ja) | 癌を治療するための物質及び方法 | |
| JP2023528415A5 (https=) | ||
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| CA3022611A1 (en) | Genetically engineered cells and methods of making the same | |
| JP2022516389A (ja) | 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 | |
| JP2018531260A5 (https=) | ||
| EP3873205B1 (en) | Materials and methods for treating cancer | |
| EP4238990A1 (en) | Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof | |
| US20230233677A1 (en) | Compositions and methods for enhancing immune response | |
| KR20240145485A (ko) | 세포-표면 수용체의 에피토프 조작 | |
| EP4476267A2 (en) | Chimeric antigen receptors binding steap1 | |
| WO2022133042A1 (en) | Cea5 binding molecules and uses thereof | |
| Caforio et al. | AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation | |
| US20240158467A1 (en) | Materials and methods for treating cancer | |
| CN114057871A (zh) | 抗人periostin单克隆嵌合抗体及应用 | |
| JP2024526851A (ja) | モノカルボン酸トランスポーター１１の阻害によるがんの細胞治療 | |
| WO2025231213A2 (en) | Modified b cells and methods for use thereof | |
| US20250249096A1 (en) | Compositions and Methods for Immunotherapy | |
| Zhang et al. | 4SCAR2. 0 therapy for the management of post-transplantation relapse of B-cell acute lymphoblastic leukemia | |
| Pedrazzani | MOBILIZATION-BASED CHEMOTHERAPY-FREE ENGRAFTMENT OF GENE EDITED HEMATOPOIETIC STEM CELLS | |
| AU2024207657A1 (en) | Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies | |
| WO2026058265A1 (en) | Compounds and methods for preparing engineered lymphocytes |